Joslin Diabetes Center, Inc.

Children's Medical Center Corporation

Children's Hospital Boston

Harvard College

C Ronald Kahn

Yu-Hua Tseng

Atul J Butte

Christine Reynet

Morris F White

Paul L Rothenberg

Leonard I Zon

Amy J Wagers

Thomas Thomou

Cong Xu

Michael Ristow

Siegfried Ussar

Jenny Gunton

This disclosure relates to the field of exosome delivery systems. In particular, compositions comprising adipose-derived exosomes that may be used as a delivery system are encompassed. The exosome delivery system can be used to deliver exogenous cargo such as miRNA and other inhibitory RNAs, as well as proteins, to target cells in a subject.

Exosome delivery system

Disclosed are methods of inducing differentiation of stem into myogenic cells without gene manipulation and for inducing proliferation of satellite cells. The cells can be used as a source of cells for transplantation in a subject in need thereof. Also disclosed is a screening assay for screening test compounds using blastomere cultures.

High-throughput image-based chemical screening in zebrafish blastomere cell culture

Provided herein are methods for increasing insulin sensitivity in a subject. A method may comprise administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent. Also provided herein are methods for determining whether a subject is or is likely to become insulin resistant. A method may comprise determining the level of glypican-4 in a subject, wherein an elevated level of glypican-4 indicates that a subject is or is likely to become insulin resistant.

Glypican-4 based compositions and methods for treating and diagnosing insulin resistance

Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7.

Methods and compositions for inducing brown adipogenesis

Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.

Methods and compositions for modulating adipocyte function

Described herein are methods for identifying and using inhibitors of Necdin function to promote brown adipose tissue (BAT) differentiation, thereby treating obesity.

Methods and compositions for modulating Necdin function

The invention provides methods of screening for compounds that increase levels or activity of Aryl hydrocarbon Nuclear Receptor Translocator (ARNT) and/or Hypoxia Inducible Factor 1&#x3b1; (HIF1&#x3b1;), for the treatment and prevention of diabetes-related disorders, including type 1 and type 2 diabetes mellitus, impaired glucose tolerance, insulin resistance and beta cell dysfunction; compounds identified by said screening methods; and methods of using said compounds. Also included are methods for treating or preventing diabetes-related diseases using ARNT and/or HIF1&#x3b1; polypeptides and polynucleotides, and for using information regarding the expression, level or activity of ARNT and/or HIF1&#x3b1; in predictive medicine, e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics.

Methods of treating diabetes

Purified DNA including a sequence encoding Diabetogene rad.

Methods for determining risk for Type I and Type II diabetes

The invention provides methods of determining whether a subject is at risk for a disorder characterized by an intermediate GAA repeat length polymorphism in the frataxin gene.

Repeat polymorphism in the frataxin gene and uses therefore

Diabetogene rad: a type II diabetes specific gene

A purified protein that is identified herein as insulin receptor substrate 1 (IRS-1) is disclosed, as well as a method of purifying IRS-1 and a recombinant nucleic acid encoding it.

Insulin receptor substrate

A purified nucleic acid consisting essentially of nucleic acid encoding insulin receptor substrate 1.

Growing community of inventors

West Newton, MA, United States of America

C Ronald Kahn